6 months ago
4
Generic drugmaker Granules India subsidiary Granules Life Sciences (GLS), located successful Hyderabad, has received U.S. Food and Drug Administration (U.S. FDA) support for a merchandise that earlier this twelvemonth was the taxable of a pre-approval inspection (PAI).
The GLS installation is present deemed approved by the U.S. FDA, marking a milestone arsenic Granules India expands its finished dosage manufacturing capabilities. This is the archetypal FDA support for the GLS site, the genitor institution said connected Tuesday (November 11, 2025). There was 1 reflection from the U.S. FDA during the inspection conducted betwixt July 28 and August 1. The institution had submitted its effect wrong the stipulated time, it said.
Granules eyes foray into peptide segment, CDMO concern with ₹192 cr. acquisition of Swiss firm
The institution plans to motorboat the approved merchandise successful the U.S. marketplace soon. The merchandise is already approved and manufactured astatine Granules’ Gagillapur facility, adjacent Hyderabad. The caller support volition assistance fortify marketplace stock and enactment concern continuity done multi-site manufacturing, Granules said, without specifying the product.
“We program connected launching the merchandise successful the U.S. marketplace soon. It is an already approved merchandise astatine our Gagillapur facility, but we program connected gathering marketplace stock with this approval,” Granules India CMD Krishna Prasad Chigurupati said successful a release.
There are besides different products filed from the aforesaid tract and expect the U.S. FDA to o.k. them pursuing indispensable audits if required. “The improvement marks the archetypal support from Granules’ 2nd Hyderabad installation with finished dosage capabilities,” helium said.
